BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27994091)

  • 1. Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events.
    Quach LT; Chang BH; Brophy MT; Soe Thwin S; Hannagan K; O'Dell JR
    Rheumatology (Oxford); 2017 Mar; 56(3):378-383. PubMed ID: 27994091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapies for active rheumatoid arthritis after methotrexate failure.
    O'Dell JR; Mikuls TR; Taylor TH; Ahluwalia V; Brophy M; Warren SR; Lew RA; Cannella AC; Kunkel G; Phibbs CS; Anis AH; Leatherman S; Keystone E;
    N Engl J Med; 2013 Jul; 369(4):307-18. PubMed ID: 23755969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
    O'Dell JR; Leff R; Paulsen G; Haire C; Mallek J; Eckhoff PJ; Fernandez A; Blakely K; Wees S; Stoner J; Hadley S; Felt J; Palmer W; Waytz P; Churchill M; Klassen L; Moore G
    Arthritis Rheum; 2002 May; 46(5):1164-70. PubMed ID: 12115219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rheumatoid Arthritis Treatment After Methotrexate: The Durability of Triple Therapy Versus Etanercept.
    Peper SM; Lew R; Mikuls T; Brophy M; Rybin D; Wu H; O'Dell J
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1467-1472. PubMed ID: 28388820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis.
    Bonafede M; Johnson BH; Tang DH; Shah N; Harrison DJ; Collier DH
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1656-63. PubMed ID: 26097194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
    Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
    Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
    Gubar' EE; Bochkova AG; Bunchuk NV
    Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
    Karlsson JA; Neovius M; Nilsson JÅ; Petersson IF; Bratt J; van Vollenhoven RF; Ernestam S; Geborek P
    Ann Rheum Dis; 2013 Dec; 72(12):1927-33. PubMed ID: 23196701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine.
    Erhardt DP; Cannon GW; Teng CC; Mikuls TR; Curtis JR; Sauer BC
    Arthritis Care Res (Hoboken); 2019 Oct; 71(10):1326-1335. PubMed ID: 30221485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
    Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
    J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
    Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewé R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
    Arthritis Res Ther; 2015 Sep; 17(1):245. PubMed ID: 26353833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis.
    O'Dell JR; Petersen K; Leff R; Palmer W; Schned E; Blakely K; Haire C; Fernandez A
    J Rheumatol; 2006 Feb; 33(2):213-8. PubMed ID: 16358366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial.
    de Jong PH; Hazes JM; Barendregt PJ; Huisman M; van Zeben D; van der Lubbe PA; Gerards AH; de Jager MH; de Sonnaville PB; Grillet BA; Luime JJ; Weel AE
    Ann Rheum Dis; 2013 Jan; 72(1):72-8. PubMed ID: 22679301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
    Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG
    J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis.
    van Vollenhoven RF; Østergaard M; Leirisalo-Repo M; Uhlig T; Jansson M; Larsson E; Brock F; Franck-Larsson K
    Ann Rheum Dis; 2016 Jan; 75(1):52-8. PubMed ID: 25873634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
    Fleischmann R; Koenig AS; Szumski A; Nab HW; Marshall L; Bananis E
    Rheumatology (Oxford); 2014 Nov; 53(11):1984-93. PubMed ID: 24907147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
    Cummins L; Katikireddi VS; Shankaranarayana S; Su KY; Duggan E; Videm V; Pahau H; Thomas R
    Intern Med J; 2015 Dec; 45(12):1266-73. PubMed ID: 26384029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoid use in rheumatoid arthritis patients and the onset of pneumonia: a systematic review and meta-analysis.
    Elsouri KN; Arboleda V; Basbous L; Heiser S; Collins DP; Ragusa P; Baxter C; Cabrera D; Akhand T; Stermer E; Sharma K; Seguro C; Hardigan P; Kesselman M; Beckler MD
    J Osteopath Med; 2023 Apr; 123(4):179-186. PubMed ID: 36691851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate.
    O'Dell JR
    Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S53-8. PubMed ID: 10589358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs].
    Jiang L; Zhao N; Ni L
    Zhonghua Liu Xing Bing Xue Za Zhi; 2002 Jun; 23(3):213-7. PubMed ID: 12411093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.